Celcuity Inc. announced that the U.S. Food and Drug Administration has accepted its New Drug Application for gedatolisib in hormone‑receptor positive, HER2‑negative, PIK3CA wild‑type advanced breast cancer. The acceptance was granted under the FDA’s Real‑Time Oncology Review program and carries a PDUFA goal date of July 17 2026, a timeline that is typically several months shorter than the standard review process.
The acceptance follows the company’s Phase 3 VIKTORIA‑1 trial, which enrolled patients receiving a triplet regimen of gedatolisib, fulvestrant, and palbociclib. The trial demonstrated a 76% reduction in the risk of disease progression and a 7.3‑month improvement in progression‑free survival compared with the control arm. These results provide the robust clinical evidence that underpins the FDA submission and justify the priority review designation.
Celcuity’s CEO Brian Sullivan said the FDA’s decision “paves the way for a potential approval and commercial launch.” He added that the company will continue to work closely with the FDA throughout the review process. The acceptance moves Celcuity from the development stage toward a possible market entry, positioning the company to capture a share of the estimated $5‑$6 billion advanced breast‑cancer market, which represents the second‑line treatment segment for hormone‑receptor positive disease.
Celcuity remains a clinical‑stage biotechnology company that has not yet generated revenue from its pipeline. The company’s financial statements show consistent net losses driven by research and development expenses, but it has secured a cash runway through 2027 via equity offerings and a term‑loan facility. The FDA acceptance therefore represents a critical milestone that could unlock future revenue and improve the company’s financial outlook.
The market reacted positively to the announcement. Analysts noted that the FDA acceptance, combined with the compelling VIKTORIA‑1 data, reinforced confidence in the drug’s potential and the company’s strategic positioning. The positive reaction was driven primarily by the regulatory milestone and the strong efficacy data, which together suggest a high likelihood of eventual approval and a meaningful commercial opportunity for Celcuity.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.